Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.
Matt Cooper, PhD
Advertisement
Executive Director and Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials
Articles by Matt Cooper, PhD
Advertisement
Latest Updated Articles
Revolutionizing Oncology: Insights on the FDA’s Project Optimus and Dose OptimizationPublished: September 20th 2024 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
